{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:58:28Z","timestamp":1767769108300,"version":"3.48.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Given the increasing number of older patients undergoing allo-HCT with post-transplant cyclophosphamide (PTCy)-based prophylaxis, a dedicated evaluation of its safety in this population is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 353 consecutive patients who underwent first allo-HCT with PTCy between 2014 and 2024. Patients were stratified into three age groups: \u226440 (24.4%), 41\u201364 (51.8%), and \u226565 (23.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age was 53 years (range 18\u201375). Older patients mostly received RIC regimens and matched unrelated donors and younger MAC and haplo-HCT. Neutrophil and platelet engraftment occurred at amedian of 18 and 17 days, without differences among age groups. The incidence of grade II-IV aGVHD at day +100 was 22.4% with no differences according to age ranges (Day +100: 16.3%, 24.0% and 25.0%, P = 0.246) and moderate-severe cGVHD in 7.4%, with incidence significantly lower in patients \u226565 years (2-year: 3.1% vs. 12.1% and 4.8%; P = 0.023). At 2-years, OS rates were 79.5% for \u226440, 73.9% for 41\u201364, and 57.9% for \u226565 years (P = 0.001). NRM rates were 7.1%, 15.6%, and 16.0% (P = 0.128), and relapse incidence rates were, respectively, 26.2%, 24.6% and 40.7% (P = 0.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite higher relapse rates leading to lower OS in older adults, similar NRM and comparable early toxicities support the feasibility of allo-HCT with PTCy in patients \u226565 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1678899","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:54:39Z","timestamp":1767768879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Allo-HCT with post-transplant cyclophosphamide in older adults: similar safety and a viable option compared to younger adults"],"prefix":"10.3389","volume":"16","author":[{"given":"Gorka","family":"Pinedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Charry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Cid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Pedraza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Queralt","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30110723","article-title":"Hematopoietic cell transplantation trends and outcomes in Canada: A registry-based cohort study","volume":"30","author":"Seftel","year":"2023","journal-title":"Curr Oncol Tor Ont"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01943-3","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey","volume":"58","author":"Passweg","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015964","article-title":"Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703","volume":"9","author":"Abedin","year":"2025","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14291","article-title":"Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide based prophylaxis","volume":"113","author":"Murillo","year":"2024","journal-title":"Eur J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bbmt.2016.09.027","article-title":"Allogeneic stem cell transplantation for patients age \u2265 70 years with myelodysplastic syndrome: A retrospective study of the MDS subcommittee of the chronic Malignancies working party of the EBMT","volume":"23","author":"Heidenreich","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02275-6","article-title":"Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Maffini","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005446","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Espa\u00f1ol de Trasplante Hematopoy\u00e9tico y Terapia Celular","author":"Fern\u00e1ndez-Luis","year":"2025","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.02.001","article-title":"Improving safety and outcomes after allogeneic hematopoietic cell transplantation: A single-center experience","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"182.e1","DOI":"10.1016\/j.jtct.2024.12.006","article-title":"Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide","volume":"31","author":"Chor\u00e3o","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285921","article-title":"Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study","volume":"110","author":"Kerbauy","year":"2025","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.008","article-title":"Bloodstream infections and outcomes following allogeneic hematopoietic cell transplantation: A single-center study","volume":"28","author":"Carreira","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0257-2","article-title":"Elderly acute myeloid leukemia: assessing risk","volume":"10","author":"Klepin","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1678899\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:54:43Z","timestamp":1767768883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1678899\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1678899"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1678899","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1678899"}}